TY - JOUR
T1 - Immunotherapy in multiple myeloma
T2 - Current strategies and future prospects
AU - Yi, Qing
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2003/6
Y1 - 2003/6
N2 - Multiple myeloma is still a fatal disease. Despite advances in high-dose chemotherapy supported by autologous transplantations, relapse of the underlying disease remains the primary cause of treatment failure. Strategies for post-transplantation immunomodulation would be desirable for eradication of remaining tumor cells. Toward this end, immunotherapy aimed at inducing myeloma-specific immunity in patients has been exploited. Idiotype protein, secreted by myeloma cells, has been the main target for immunotherapy as it is the best-defined, tumor-specific antigen. The focus of this review article is the use of idiotype as a form of protein antigen to immunize patients, to load dendritic cells, or as part of DNA vaccines. Various strategies of immunotherapy and the outcome of clinical trials are also discussed.
AB - Multiple myeloma is still a fatal disease. Despite advances in high-dose chemotherapy supported by autologous transplantations, relapse of the underlying disease remains the primary cause of treatment failure. Strategies for post-transplantation immunomodulation would be desirable for eradication of remaining tumor cells. Toward this end, immunotherapy aimed at inducing myeloma-specific immunity in patients has been exploited. Idiotype protein, secreted by myeloma cells, has been the main target for immunotherapy as it is the best-defined, tumor-specific antigen. The focus of this review article is the use of idiotype as a form of protein antigen to immunize patients, to load dendritic cells, or as part of DNA vaccines. Various strategies of immunotherapy and the outcome of clinical trials are also discussed.
KW - Dedritic cells
KW - Idiotype
KW - Immunotherapy
KW - Multiple myeloma
KW - T-cells
UR - http://www.scopus.com/inward/record.url?scp=0038171328&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0038171328&partnerID=8YFLogxK
U2 - 10.1586/14760584.2.3.391
DO - 10.1586/14760584.2.3.391
M3 - Review article
C2 - 12903804
AN - SCOPUS:0038171328
SN - 1476-0584
VL - 2
SP - 391
EP - 398
JO - Expert Review of Vaccines
JF - Expert Review of Vaccines
IS - 3
ER -